Aflibercept

Summary

Aflibercept (CHEMBL1742982) is an approved protein (ATC L01XX44); indicated across 53 conditions including colorectal adenocarcinoma and diabetic retinopathy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L01XX44 (+1 more)
• Indications: 53 conditions
• Clinical trials: 365

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1742982
Name	Aflibercept
Type	Protein
Max phase	4
ATC	L01XX44, S01LA05

Also known as: ABP-938, Aflibercept, Aflibercept (genetical recombination), Aflibercept beta, Aflibercept biosimilar (amgen), Aflibercept biosimilar (lubt-017), Aflibercept recombinant, Aflibercept-abzv, Aflibercept-ayyh, Aflibercept-jbvf, Aflibercept-mrbb, Aflibercept-yszy

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

53 indications (12 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
colorectal adenocarcinoma	4	MONDO:0005008	EFO:0000365
diabetic retinopathy	4	MONDO:0005266	EFO:0003770
ocular vascular disorder	4	MONDO:0005552	EFO:0005753
wet macular degeneration	4	MONDO:0005417	EFO:0004683
neoplasm	4	MONDO:0005070	EFO:0000616
retinal vein occlusion	4	MONDO:0006951	EFO:1001157
colorectal neoplasm	4	MONDO:0005335	EFO:0004142
degenerative myopia	4	MONDO:0001383	EFO:0004207
age-related macular degeneration	3	MONDO:0005150	EFO:0001365
melanoma	3	MONDO:0005105	EFO:0000756
cutaneous melanoma	3	MONDO:0005012	EFO:0000389
metastatic melanoma	3	MONDO:0005191	EFO:0002617
neovascular glaucoma	3	MONDO:0019783	EFO:1001060
macular degeneration	3	MONDO:0003004	EFO:0009606
retinopathy of prematurity	3	MONDO:0006952	EFO:1001158
telangiectasis	3	MONDO:0001576	MONDO:0001576
glaucoma	3	MONDO:0005041	MONDO:0005041
choroidal neovascularization	3	MONDO:0810000	MONDO:0810000
retinal disorder	2	MONDO:0005283	EFO:0003839
carcinoid tumor	2	MONDO:0005369	EFO:0004243
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
rectal cancer	2	MONDO:0006519	EFO:1000657
thyroid gland follicular carcinoma	2	MONDO:0005034	EFO:0000501
leukemia	2	MONDO:0005059	EFO:0000565
thyroid gland papillary carcinoma	2	MONDO:0005075	EFO:0000641
renal cell carcinoma	2	MONDO:0005086	EFO:0000681
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
anaplastic astrocytoma	2	MONDO:0016684	EFO:0002499
anaplastic oligodendroglioma	2	MONDO:0016696	EFO:0002501
gliosarcoma	2	MONDO:0016681	EFO:1001465
endometrial carcinoma	2	MONDO:0002447	EFO:1001512
central serous chorioretinopathy	2	MONDO:0018616	EFO:0009784
breast neoplasm	2	MONDO:0021100	MONDO:0007254
colonic neoplasm	2	MONDO:0005401	MONDO:0021063
brain neoplasm	2	MONDO:0021211	EFO:0003833
uveal melanoma	2	MONDO:0006486	EFO:1000616
autosomal recessive inherited pseudoxanthoma elasticum	2	MONDO:0009925	MONDO:0009925
histoplasmosis	1	MONDO:0018312	EFO:0007310
non-Hodgkin lymphoma	1	MONDO:0018908	EFO:0005952
corneal neovascularization	1	MONDO:0006713	EFO:1000880
lymphoma	1	MONDO:0005062	EFO:0000574
non-small cell lung carcinoma	1	MONDO:0005233	EFO:0003060
glioma	1	MONDO:0021042	MONDO:0003268
glioblastoma	1	MONDO:0018177	MONDO:0020690

9 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 365.

Phase distribution

Phase	Trials
PHASE2	87
PHASE3	80
PHASE4	70
Not specified	69
PHASE1	34
PHASE1/PHASE2	16
PHASE2/PHASE3	8
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04469595	PHASE4	ACTIVE_NOT_RECRUITING	A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
NCT06683950	PHASE4	RECRUITING	Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment
NCT06850571	PHASE4	RECRUITING	Aflibercept and Bevacizumab for Diabetic Maculopathies
NCT07118670	PHASE4	ACTIVE_NOT_RECRUITING	High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes
NCT07301775	PHASE4	NOT_YET_RECRUITING	Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery
NCT01495208	PHASE4	WITHDRAWN	Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment
NCT01543568	PHASE4	COMPLETED	Study for Recalcitrant Age Related Macular Degeneration
NCT01617148	PHASE4	COMPLETED	Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
NCT01670162	PHASE4	UNKNOWN	On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
NCT01722656	PHASE4	COMPLETED	Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment
NCT01824225	PHASE4	COMPLETED	Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration
NCT01857544	PHASE4	UNKNOWN	Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy
NCT01870427	PHASE4	COMPLETED	NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions
NCT01896284	PHASE4	COMPLETED	Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor
NCT01918878	PHASE4	UNKNOWN	Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.
NCT01950741	PHASE4	COMPLETED	Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
NCT01958918	PHASE4	COMPLETED	Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
NCT01961414	PHASE4	UNKNOWN	Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910
NCT02002377	PHASE4	TERMINATED	Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections
NCT02033018	PHASE4	UNKNOWN	Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization
NCT02072408	PHASE4	COMPLETED	Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy
NCT02120950	PHASE4	COMPLETED	Aflibercept in Polypoidal Choroidal Vasculopathy
NCT02130024	PHASE4	COMPLETED	A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
NCT02142296	PHASE4	COMPLETED	Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)
NCT02257632	PHASE4	COMPLETED	Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration
NCT02258009	PHASE4	WITHDRAWN	Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
NCT02274259	PHASE4	COMPLETED	Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen
NCT02297204	PHASE4	COMPLETED	The Endurance 1 Trial
NCT02299336	PHASE4	COMPLETED	Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial
NCT02305238	PHASE4	COMPLETED	Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration
NCT02309281	PHASE4	COMPLETED	Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab
NCT02320474	PHASE4	COMPLETED	Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)
NCT02321267	PHASE4	UNKNOWN	Cohort Study of the Clinical Course of Macular Diseases in Kagawa
NCT02432547	PHASE4	COMPLETED	Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO)
NCT02441816	PHASE4	COMPLETED	VITAL - Individualising Therapy for Neovascular AMD With Aflibercept
NCT02441907	PHASE4	COMPLETED	Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema
NCT02495181	PHASE4	COMPLETED	Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy
NCT02503540	PHASE4	COMPLETED	Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO
NCT02559180	PHASE4	COMPLETED	Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab
NCT02581891	PHASE4	COMPLETED	Managing Neovascular (Known as Wet) Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).